Psychiatry and Neurology, Neurology · Greenville, SC
NPI
1003013616
Since 2007
Specialty
Psychiatry and Neurology, Neurology
Code 2084N0400X
Group practices
3
Medicare group memberships
Hospitals
2
Hospital affiliations
801 Roper Creek Dr
Greenville, SC, 29615
Phone (864) 516-1170
Groups this clinician bills Medicare through
Medicare paid, 2024
$522K
66,730 services
Medicare patients, 2024
401
Average age 76
Drug cost, 2024
$2.5M
4,572 prescriptions
Company payments, 2025
$912
From 14 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Kathleen V Woschkolup was code J0585 (injection, onabotulinumtoxina, 1 unit), 43,093 times for 65 patients. In total Kathleen V Woschkolup billed 66,730 services in 42 codes, and Medicare paid $522K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2016-12-01.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J0585 Injection, onabotulinumtoxina, 1 unit | Office | 43,093 | 65 | $4.86 | $209K |
| J1439 Injection, ferric carboxymaltose, 1 mg | Office | 9,750 | 13 | $0.89 | $8,635 |
| J0588 Injection, incobotulinumtoxin a, 1 unit | Office | 4,390 | 14 | $4.09 | $18K |
| J0897 Injection, denosumab, 1 mg | Office | 3,180 | 46 | $20.15 | $64K |
| 99215 Office E&M - Established | Office | 497 | 261 | $122.14 | $61K |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 305 | 220 | $12.31 | $3,754 |
| 95874 Musculoskeletal | Office | 139 | 48 | $46.04 | $6,399 |
| G2212 Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | Office | 134 | 105 | $21.13 | $2,831 |
| 95984 Electrical Nerve Conductivity | Office | 110 | 22 | $31.86 | $3,505 |
| 64616 Musculoskeletal | Office | 85 | 26 | $133.64 | $11K |
| 95983 Electrical Nerve Conductivity | Office | 65 | 24 | $35.10 | $2,281 |
| 64612 Musculoskeletal | Office | 64 | 21 | $112.63 | $7,208 |
| 96372 Injection Administration | Office | 61 | 49 | $9.05 | $552 |
| 96365 Intravenous Infusion, Hydration | Office | 48 | 31 | $45.28 | $2,173 |
| 99205 Office E&M - New | Office | 45 | 45 | $151.68 | $6,826 |
By year: 2022 $301K for 40,086 services; 2023 $363K for 42,044 services; 2024 $522K for 66,730 services.
Medicare prescription drug claims, 2024
In 2024, the drug Kathleen V Woschkolup prescribed most often to Medicare patients was Carbidopa-Levodopa (Carbidopa/Levodopa), with 795 prescriptions and refills. In total Kathleen V Woschkolup wrote 4,572 Medicare prescriptions that cost $2.5M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Carbidopa-Levodopa Carbidopa/Levodopa | 795 | 1,942 | 216 | $40K |
| Carbidopa-Levodopa Er Carbidopa/Levodopa | 614 | 1,465 | 182 | $30K |
| Clonazepam Generic | 314 | 548 | 90 | $2,775 |
| Nuplazid Pimavanserin Tartrate | 259 | 285 | 28 | $1.4M |
| Quetiapine Fumarate Generic | 199 | 403 | 53 | $3,688 |
| Rytary Carbidopa/Levodopa | 182 | 318 | 29 | $304K |
| Ropinirole Hcl Generic | 169 | 363 | 47 | $6,943 |
| Rivastigmine Rivastigmine Tartrate | 131 | 293 | 45 | $12K |
| Amantadine Amantadine Hcl | 124 | 302 | 37 | $5,446 |
| Primidone Generic | 115 | 318 | 35 | $3,024 |
| Sertraline Hcl Generic | 101 | 217 | 26 | $884 |
| Gocovri Amantadine Hcl | 100 | 130 | 16 | $418K |
| Fludrocortisone Acetate Generic | 83 | 231 | 29 | $2,855 |
| Buspirone Hcl Generic | 81 | 162 | 30 | $1,593 |
| Memantine Hcl Generic | 73 | 149 | 20 | $4,913 |
Brand drugs: 723 claims; generic drugs: 3,849 claims; opioid claims: 26.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Kathleen V Woschkolup $912 ($912 in general payments such as food, travel and fees) from 14 companies. The largest payer was Teva Pharmaceuticals USA, Inc. with $293.
| Company | Payments | Amount |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. TEVA | 7 | $293 |
| Supernus Pharmaceuticals, Inc. SUPN | 9 | $205 |
| Abbvie Inc. ABBV | 4 | $66.67 |
| TG Therapeutics, Inc. TGTX | 2 | $55.99 |
| Pfizer Inc. PFE | 3 | $54.5 |
| Neurocrine BioSciences, Inc. NBIX | 2 | $41.28 |
| Biogen, Inc. BIIB | 2 | $41.05 |
| Argenx US, Inc. ARGX | 1 | $33.97 |
| CSL Behring CSL.AX | 1 | $29.33 |
| Takeda Pharmaceuticals U.S.A., Inc. TAK | 1 | $28.56 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.